HK1088849A1 - Blood-viscosity reducing agent - Google Patents

Blood-viscosity reducing agent

Info

Publication number
HK1088849A1
HK1088849A1 HK06110957.4A HK06110957A HK1088849A1 HK 1088849 A1 HK1088849 A1 HK 1088849A1 HK 06110957 A HK06110957 A HK 06110957A HK 1088849 A1 HK1088849 A1 HK 1088849A1
Authority
HK
Hong Kong
Prior art keywords
alanine
glycine
acid
aspartic acid
valine
Prior art date
Application number
HK06110957.4A
Other languages
English (en)
Inventor
Masahito Hitosugi
Hiroaki Maeda
Kazunobu Omura
Original Assignee
Daiwa Pharmaceutical Co Ltd
Masahito Hitosugi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiwa Pharmaceutical Co Ltd, Masahito Hitosugi filed Critical Daiwa Pharmaceutical Co Ltd
Publication of HK1088849A1 publication Critical patent/HK1088849A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK06110957.4A 2004-11-16 2006-10-03 Blood-viscosity reducing agent HK1088849A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004331559A JP2006143601A (ja) 2004-11-16 2004-11-16 血液粘度低下剤

Publications (1)

Publication Number Publication Date
HK1088849A1 true HK1088849A1 (en) 2006-11-17

Family

ID=34993180

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06110957.4A HK1088849A1 (en) 2004-11-16 2006-10-03 Blood-viscosity reducing agent

Country Status (10)

Country Link
US (2) US20060105071A1 (zh)
EP (1) EP1657304B1 (zh)
JP (1) JP2006143601A (zh)
KR (1) KR100709300B1 (zh)
CN (1) CN1775284B (zh)
AT (1) ATE446360T1 (zh)
CA (1) CA2527154A1 (zh)
DE (1) DE602005017235D1 (zh)
HK (1) HK1088849A1 (zh)
TW (1) TWI284537B (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1857722A (zh) * 2005-04-30 2006-11-08 成都地奥九泓制药厂 蜡样芽孢杆菌在制备治疗血栓疾病药物中的用途
WO2007002572A2 (en) * 2005-06-24 2007-01-04 N-Zymeceuticals, Inc. Nattokinase for reducing whole blood viscosity
SG10201510384UA (en) 2006-09-13 2016-01-28 Abbvie Inc Cell culture improvements
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
CA2738499A1 (en) 2008-10-20 2010-04-29 Abbott Laboratories Viral inactivation during purification of antibodies
AU2009347206C1 (en) 2008-10-20 2016-12-08 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
CN109666603B (zh) * 2018-12-19 2021-11-26 武汉科诺生物科技股份有限公司 一种生产低黏度多粘类芽孢杆菌发酵液的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61162184A (ja) 1985-01-10 1986-07-22 Noriyoshi Morimoto 新規な線溶酵素およびその取得法
JP2688603B2 (ja) 1988-01-13 1997-12-10 日本ケミカルリサーチ株式会社 血栓溶解剤
JPH0813271B2 (ja) 1989-11-27 1996-02-14 日本ケミカルリサーチ株式会社 線溶活性蛋白質およびその製造法
JPH06153977A (ja) 1992-11-16 1994-06-03 Japan Energy Corp 線溶活性を持つ蛋白質の製造法
JP3168082B2 (ja) 1992-12-24 2001-05-21 キヤノン株式会社 テープローディング機構
JPH08208512A (ja) 1995-02-03 1996-08-13 Nippon Chem Res Kk 血栓形成阻害剤
US6395889B1 (en) * 1999-09-09 2002-05-28 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding human protease homologs
AUPQ387599A0 (en) * 1999-11-05 1999-12-02 Metabolic Pharmaceuticals Limited Product and method for control of obesity
US6866851B1 (en) * 1999-12-28 2005-03-15 Washington University GFRα1-RET specific agonists and methods therefor
JP3881494B2 (ja) * 2000-04-21 2007-02-14 株式会社日本生物科学研究所 納豆菌培養エキス
JP3532503B2 (ja) 2000-06-14 2004-05-31 大和薬品株式会社 加工食品および食品加工方法
TWI305778B (en) * 2001-12-03 2009-02-01 Nishida Teruo Peptides of an expressing unit for igf-i minimal activity and their pharmaceutical use
CN1451745A (zh) * 2002-04-15 2003-10-29 黑龙江省科学院应用微生物研究所 利用枯草芽孢杆菌生产的纳豆激酶及其生产方法和用途
US20040043014A1 (en) * 2002-08-30 2004-03-04 Hiroyoshi Moriyama Platelet aggregation inhibitor and supplement food effective for inhibiting platelet aggregation
US7795385B2 (en) * 2004-12-17 2010-09-14 Bexar Global, Inc. Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder

Also Published As

Publication number Publication date
ATE446360T1 (de) 2009-11-15
CN1775284A (zh) 2006-05-24
EP1657304B1 (en) 2009-10-21
CN1775284B (zh) 2011-01-26
JP2006143601A (ja) 2006-06-08
US20090202982A1 (en) 2009-08-13
KR100709300B1 (ko) 2007-04-20
US20060105071A1 (en) 2006-05-18
US7972835B2 (en) 2011-07-05
CA2527154A1 (en) 2006-05-16
EP1657304A1 (en) 2006-05-17
KR20060055302A (ko) 2006-05-23
TWI284537B (en) 2007-08-01
DE602005017235D1 (de) 2009-12-03

Similar Documents

Publication Publication Date Title
HK1088849A1 (en) Blood-viscosity reducing agent
TW200509899A (en) Amino acid composition and supplemental solution
MXPA03010103A (es) Peptidos y composiciones anti-microbianos.
RS50966B (sr) Agonisti pyy i njihova upotreba
DK1144607T5 (da) Fremgangsmåde til præsentation af (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger
BRPI0512396A (pt) polipeptìdeos biossintéticos utilizando aminoácidos codificados não naturalmente
ECSP044996A (es) Agentes de contraste de objetivo multimérico basado en péptido
ATE551048T1 (de) Proteinhydrolysate enthaltende kosmetische zusammensetzungen
EP2298331A3 (en) Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
CY1110280T1 (el) Διαδικασια παρασκευης μιγματος πολυπεπτιδιων χρησιμοποιωντας καθαρισμενο υδροβρωμικο οξυ
NZ579566A (en) Modified fgf-21 polypeptides and their uses
EP1908492A4 (en) METABOTROPIC GLUTAMATE RECEPTOR ACTIVATOR
ATE491349T1 (de) Neue nutrazeutika-zusammensetzungen
DE69723812D1 (de) Aminosäurezusammensetzungen
ATE418877T1 (de) Essbare bzw. trinkbare sowie medizinisch verwendbare, die körpertemperatur erhöhende aminosäurezusammensetzung
BRPI0607000A2 (pt) composição de liberação constante de fármaco de proteìna
BRPI0507186A (pt) composição, métodos e usos para uma nova famìlia de peptìdeos
EP2196203A3 (en) Use of amino-acid based compositions for the treatment of sarcopenia
CA3010982A1 (en) Alpha chain of the high-affinity ige receptor (fceria)
ES2178207T3 (es) Nuevos derivados de triptolida utiles en el tratamiento de enfermedades autoinmunes.
DK1204679T3 (da) Peptider som indeholder N-substituerede D-aminosyrer til at forhindre associering af Beta-strenge
WO2018130212A3 (zh) 胃蛋白抗性改良和催化效率提高的植酸酶YkAPPA突变体
DE602004028266D1 (de) Angiogene peptide und ihre verwendungen
ATE459332T1 (de) Kosmetisches oder therapeutisches kombinationspräparat mit theanin
WO2003018045A1 (fr) Medicament a utiliser pour le traitement des infections a vih, composition et utilisations correspondantes